指南与共识心力衰竭与心肌病心律失常

心脏结节病管理专家共识解读

Management of cardiac sarcoidosis.
指南 / 共识 · Eur Heart J · 2024-01-01

该专家共识声明总结了心脏结节病(CS)的诊断工具与多学科方法,基于有限证据和国际专家经验,提出免疫抑制治疗及心脏并发症处理的建议,并涵盖监测与风险分层。

要点

  • CS可导致高度房室传导阻滞、室性心动过速、心衰及心源性猝死。
  • 强调整合临床信息与诊断检查以准确及时诊断并排除替代诊断。
  • 基于有限数据推荐免疫抑制及心脏并发症的治疗策略。

核心结论

  • 心脏结节病是炎症性心肌病,需多学科方法整合临床与检查结果以准确诊断。
  • 基于有限发表数据与国际专家经验,提供免疫抑制及心脏并发症治疗建议。

研究设计与样本

  • 欧洲心脏病学会(Eur Heart J)发布的临床专家共识声明。

主要发现

  • CS与高度房室传导阻滞、室性心动过速、心衰及心源性猝死相关。

临床怎么用

  • 临床医生应整合临床信息与诊断检查结果,及时诊断CS并排除替代诊断。
  • 根据共识建议对CS患者进行免疫抑制治疗和心脏并发症管理。
  • 对CS患者进行监测和风险分层。

局限性

  • 建议基于有限已发表数据及国际专家经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sharma R, Kouranos V, Cooper LT, et al. Management of cardiac sarcoidosis. Eur Heart J. 2024. PMID: 38923509. doi:10.1093/eurheartj/ehae356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。